Ezetimibe Versus Nutraceuticals in Statin-intolerant Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT01490229

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01490229
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01490229. Randomized; single masking; primary purpose treatment. Start 2013-01 (registry gives no type); primary completion 2014-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ezetimibe Versus Nutraceuticals in Statin-intolerant Patients
Acronym
ECLIPSE
Intervention (Drug)
Ezetimibe
Intervention (Drug)
Nutraceuticals
Lead sponsor
University of Roma La Sapienza (class: other)

Record details

Record id
cardio:ct-nct01490229
Content hash
1be9e7a359048704d2cdc19e31bc76e3e3e8cde66f09d865e1d128f65b8994d3